Skip to content

Rosa M Dueñas

ANIMA Group. Institut de Recerca Sant Joan de Déu (IRSJD), Esplugues de Llobregat, Spain.

1 paper in the library · publishing 2026

Papers

Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy.

Natural product research June 2, 2026 Genís Ona, Cristina Llagostera, Oscar Alvarez et al.

Psilocybin from Psilocybe cubensis mushrooms shows therapeutic potential, but current research focuses only on isolated psilocybin, ignoring the whole mushroom's broader pharmacology and cultural use. This perspective advocates for studying standardized whole-mushroom extracts. Preclinical studies comparing whole extracts with pure psilocybin reveal enhanced or distinct effects on synaptic proteins, metabolomic profiles, and behavioral outcomes in models of depression and obsessive-compulsive disorder. Whole extracts may also enable more affordable and equitable treatment models than high-cost synthetic psilocybin. The article argues for urgent exploration of whole-mushroom therapeutics to base psychedelic medicine on a full spectrum of evidence.